Successful treatment of a cervical ectopic pregnancy with single-dose methotrexate therapy by Dearworth, Hannah & Cottrell, Jesse
Volume 6 Issue 3 Article 8 
2020 
Successful treatment of a cervical ectopic pregnancy with single-dose 
methotrexate therapy 
Hannah Dearworth and Jesse Cottrell 
Author Affiliations 
Hannah Dearworth (Marshall University, Huntington, West Virginia) 
Jesse Cottrell (Marshall University, Huntington, West Virginia) 
Corresponding Author 
Hannah Dearworth MD 
Marshall University 
Huntington, West Virginia 
Email: johnsonha@marshall.edu 
Follow this and additional works at: https://mds.marshall.edu/mjm 
 Part of the Medicine and Health Sciences Commons 
This work is licensed under a Creative Commons Attribution 4.0 License. 
Recommended Citation 
Dearworth, Hannah and Cottrell, Jesse (2020) "Successful treatment of a cervical ectopic pregnancy with single-dose 
methotrexate therapy," Marshall Journal of Medicine: Vol. 6: Iss. 3, Article 8. 
DOI: 10.33470/2379-9536.1293 
Available at: https://mds.marshall.edu/mjm/vol6/iss3/8 
DOI: 10.33470/2379-9536.1293 
Open Access | 





Ectopic pregnancies implanted in the cervix account for less than one percent of all extra-uterine 
pregnancies. Due to the rare incidence of cervical ectopic pregnancies, there are no established 
guidelines for medical versus surgical management. We report a case of a cervical ectopic 








An ectopic pregnancy is a pregnancy that is implanted outside of the uterus, most commonly 
within the fallopian tube, but can occur in other rare sites such as the cervical canal. Cervical 
ectopic pregnancies occur in 1 in 9000 pregnancies.1,2 An ectopic pregnancy implanted in the 
cervical canal is considered a non-viable gestation with high risk for maternal morbidity and 
mortality. Prior reports describe multi-dose methotrexate therapy for an embryo with no fetal 
pole, and direct potassium chloride (KCL) injection into the gestational sac if a heartbeat is 
present.3 We report a case of a cervical ectopic pregnancy with a fetal heartbeat successfully 
treated with single-dose methotrexate therapy.  
   
Case Description  
 
A 22-year-old gravida 2 para 0 at 6 weeks and 5 days gestational age by the last menstrual 
period presented to the emergency room with heavy vaginal bleeding. A previous dating and 
viability transvaginal ultrasound at her OB/GYN’s office was suspicious for a cervical ectopic 
pregnancy. She reported no previous medical conditions. The patient’s obstetric history was 
significant for a previous dilation and curettage at 7 weeks and 3 days gestation due to a 
spontaneous abortion. She denied any sexually transmitted infections.  
 
On physical exam, the patient’s abdomen was soft, non-tender and non-distended. Initial vital 
signs were temperature 97.6 F, pulse 77, blood pressure 109/68. Sterile speculum exam was 
performed, and clotted blood was observed protruding from the external cervical os. 
Transvaginal ultrasound was performed and demonstrated an intracervical pregnancy with a 
crown-rump length of 6.8 mm, a gestational sac measuring 9.9 mm, a yolk sac measuring 3.0 
mm, and a fetal heart rate of 113 beats per minute (Figure 1 and Figure 2). A maternal-fetal 
medicine specialist was consulted, and the diagnosis of a cervical ectopic pregnancy was 
confirmed. The patient’s left and right ovaries were visualized and appeared normal with a 
suspected right corpus luteum cyst. The initial beta-human chorionic gonadotropin (HCG) 
quantitative measurement was 5688 mIU/mL. The initial hemoglobin/hematocrit (Hgb/Hct) level 
was 14.0/42.1 and the patient was typed and cross-matched.  
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Figure 2: 3D Rendering of Pregnancy Implanted in the Cervical Canal
 
  
After counseling the patient on the ultrasound and laboratory findings, routes of administration 
were discussed. These included single-dose methotrexate, multiple-dose methotrexate or KCL 
injection for a cervical ectopic pregnancy. She elected to proceed with single-dose methotrexate 
therapy. Methotrexate 50 mg/m2 was given to the patient, for a total dose of 84.5 mg.  
 
One day following methotrexate administration (post-injection day 1), cardiac activity was again 
demonstrated on ultrasound, and repeat beta-HCG quantitative measurement was 5587 mIU/mL. 
Following the ultrasound, the patient began experiencing nausea and then heavy vaginal bleeding 
requiring the use of three pads over six hours. She never became hemodynamically unstable, and 
repeat measurement of Hgb/Hct 12.2/36.6 was reassuring. A transvaginal ultrasound performed 
the following morning (post-injection day 2) showed no evidence of intracervical pregnancy. Her 
beta-HCG quantitative measurement decreased to 1856 mIU/mL. The patient then signed out 




Cervical ectopic pregnancies account for less than 1 percent of all ectopic pregnancies.4,5 Early 
diagnosis and treatment are critical in cervical pregnancies due to the high risk of maternal 
morbidity and mortality, primarily due to severe hemorrhage.6  
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The most common presenting symptom of a cervical ectopic pregnancy is vaginal bleeding, 
which is often painless and profuse. The differential diagnosis for painless vaginal bleeding in 
early pregnancy includes ectopic pregnancy, miscarriage, implantation bleeding, and gestational 
trophoblastic disease.7  
  
Management is primarily dictated by the patient’s hemodynamic status. In a stable patient, the 
mainstay of diagnosis is transvaginal ultrasound and physical exam coupled 
with serial serum beta HCG levels following treatment. Due to the rare incidence of cervical 
ectopic pregnancies, there are no established guidelines for medical versus surgical management. 
Existing literature from case reports and case series suggests initial treatment with multi-dose 
methotrexate therapy if there is no fetal heartbeat, and direct intra-amniotic potassium 
chloride (KCL) injection if a fetal heartbeat is present.8 While methotrexate has a higher chance 
of failure, intra-amniotic KCL injection is associated with maternal hemorrhage when the 
gestational sac collapses.9 Methotrexate interferes with DNA synthesis, repair, and cellular 
replication by inhibiting DHFR, which depletes the cellular pools. Some absolute 
contraindications to methotrexate therapy are active pulmonary disease, alcoholism, 
breastfeeding, hematologic dysfunction, immunodeficiency syndrome, peptic ulcer disease and 
renal disease.10 
 
In fallopian tube ectopic pregnancies, two-dose methotrexate is recommended if the beta-HCG 
quantitative is above 3,000 mIU/mL or if the mass measures greater than two cm. Multi-dose 
methotrexate is another option for cervical ectopic pregnancies and requires 1mg/kg per day on 
days 1, 3, 5, and 7 combined with IM leucovorin 0.1 mg/kg on days 2, 4, 6, and 8. A single dose 
approach is less expensive, requires less intensive monitoring and has fewer adverse effects.11 In 
this current case, our patient elected for a more conservative management with single-dose 
methotrexate therapy. In light of the patient’s stable hemodynamic status and ability to provide 
inpatient monitoring during and after treatment with methotrexate, this approach with 
methotrexate therapy alone was considered a reasonable option in this case. An early gestational 
age of 6 weeks and 5 days could have contributed to the success of single-dose methotrexate 
therapy in this case. A limitation in this case was that the beta-HCG levels could not be followed 
to zero due to the patient leaving against medical advice. Repeat imaging demonstrated 
resolution of the cervical ectopic pregnancy, and repeat beta-HCG levels significantly declined. 
Serial HCG levels should be obtained until a nonpregnancy level is achieved, which may take up 
to eight weeks. Failure of the HCG level to decrease by at least 15% from day four to day seven 
after methotrexate administration is associated with treatment failure and additional methotrexate 
or surgical intervention may be considered.10  
 
Cervical ectopic pregnancies are uncommon. When counseling patients regarding their options 
for the treatment of cervical ectopic pregnancies, a shared decision-making model should be 
employed when determining how to treat these non-viable pregnancies. A conservative approach 
with single-dose methotrexate therapy was successful in this case even though a fetal heartbeat 
was present on ultrasound.  
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